/Investor DB

Two Bear Capital — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

CIQciq.comin𝕏May 2022 · $26M✓ verified

CIQ is an enterprise infrastructure software company that builds and supports the Linux, HPC, and AI infrastructure stack from the kernel to the orchestrator, serving enterprises, research institutions, and government agencies.

AI & Machine LearningCloud ComputingData & InfrastructureDeveloper ToolsReno, US

Gregory Kurtzer(Founder & CEO)inBjorn Hovland(President)inPeter Nelson(Chief Technology Officer)inMarlin Prager(CFO)in

Co-investorsRho Capital PartnersRho Ventures

Arch Systemsarchsys.ioin𝕏Jul 2022 · $15M

Arch builds agentic AI that acts as a virtual factory expert, analyzing manufacturing data to identify root causes and give operators, engineers, and shift leaders prescriptive next steps in real time.

Advanced ManufacturingAI & Machine LearningIoTPalo Alto, US

Andrew Scheuermann(CEO & Co-founder)inTim Burke(CTO & Co-founder)inJennifer Davis(Chief Operating Officer)inBen Freeman(SVP of Engineering)inGus Shahin(Director)

Board seatMichael Goguen· per SEC Form D

Co-investorsCapmontComet LabsHCVCMerus CapitalNeotribe VenturesStartX+3 more

Novoron Biosciencenovoron.comin𝕏Dec 2022 · $3M

Novoron develops lipoprotein-receptor small molecule therapies aimed at repairing damage and degeneration of the brain and spinal cord, including treatments for proteinopathies and neuroregeneration following traumatic injury.

BiotechDeep TechHealthtechMedical DevicesSan Diego, US

Travis Stiles(CEO & Co-founder)inShawn Gahr(COO & Co-founder)inDavid Weiner(Executive Chairman)Ryan McMillian(CFO & Financial Strategy)

Board seatMichael Goguen· per SEC Form D

Co-investorsPhase Two VenturesBackstage Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Abilita Bio

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.